Preclinical and clinical studies on Qin-Zhu-Liang-Xue decoction:insights from network pharmacology and implications for atopic dermatitis treatment  

作　　者：Keke Huang Qingkai Liu Ruoxi Zhang Hua Nian Ying Luo Yue Luo Xiaoya Fei Le Kuai Bin Li Yimei Tan Su Li Xin Ma 

机构地区：[1]Department of Dermatology,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai,200437,China [2]Shanghai Skin Disease Hospital,Institute of Dermatology,School of Medicine,Tongji University,Shanghai,200443,China [3]Institute of Dermatology,Shanghai Academy of Traditional Chinese Medicine,Shanghai,201203,China [4]Pharmaceutical Center of Yueyang Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,200437,China [5]NMPA Key Laboratory for Monitoring and Evaluation of Cosmetics,Shanghai,200443,China

出　　处：《Frontiers of Medicine》2025年第1期134-148,F0004,共16页医学前沿(英文版)

基　　金：supported by the National Natural Science Foundation of China(No.82004359);Xinglin Youth Scholar of Shanghai University of Traditional Chinese Medicine(No.RY411.33.10);Youth Talent Promotion Project of China Association of Traditional Chinese Medicine(2021-2023)Category A(No.CACM-2021-QNRC2-A10);Health Young Talents of Shanghai Municipal Health Commission(No.2022YQ026);“Chen Guang”project supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation(No.22CGA50);The Clinical Research Plan of SHDC(No.SHDC22022302);High-level Chinese Medicine Key Discipline Construction Project(Integrative Chinese and Western Medicine Clinic)of National Administration of TCM(No.zyyzdxk-2023065);Shanghai Dermatology Research Center(No.2023ZZ02017);Shanghai Dermatology Hospital Demonstration Research Ward Project(No.SHDC2023CRW009);Evidence-based Dermatology Base sponsored by State Administration of Traditional Chinese Medicine,Shanghai Municipal Project for the Construction of Traditional Chinese Medicine Expert Heritage Studio(No.2020ZYGZS-002);Clinical Transformation Incubation Program in Hospital(No.lczh2023-01);Professional Technical Service Platform Construction Project of Shanghai Science and Technology Commission(No.21DZ2294500);Shanghai key Discipline Construction Project of Traditional Chinese Medicine(No.shzyyzdxk-2024104).

摘　　要：To investigate the protective effects and underlying mechanisms of Qin-Zhu-Liang-Xue decoction(QZLX)in atopic dermatitis(AD)and glucocorticoid resistance,we conducted a single-blinded,randomized controlled clinical trial to evaluate the efficacy and safety of this concoction.Network pharmacology analysis was performed and validated through clinical studies.The efficacy,safety,and mechanism of action of QZLX and glucocorticoid receptor(GR)αrecombinant protein were assessed in AD mice induced by 2,4-dinitrofluorobenzene(DNFB).Correlation analysis was performed to determine the clinical relevance of GRα.The trial demonstrated that patients who received QZLX showed considerable improvements in their Scoring Atopic Dermatitis(SCORAD)and Dermatology Life Quality Index(DLQI)scores compared with those who received mizolastine at week 4.Network pharmacological analysis identified GRαas a key target for QZLX in AD treatment.QZLX administration increased the serum GRαexpression in AD patients,alleviated AD symptoms in mice,decreased inflammatory cytokine expression,and increased GRαexpression without affecting liver or kidney function.In addition,GRαrecombinant protein improved AD-like skin lesions in DNFB-induced mice.A negative correlation was observed between GRαexpression and clinical parameters,including SCORAD,DLQI,and serum IgE levels.QZLX alleviates AD symptoms through the upregulation of GRαand thus presents a novel therapeutic strategy for the prevention of glucocorticoid resistance in AD management.

关 键 词：Qin-Zhu-Liang-Xue decoction atopic dermatitis glucocorticoid receptorα traditional Chinese medicine network pharmacology 

分 类 号：R73[医药卫生—肿瘤]